EPS: As of FY2025 Q1, the actual value is USD 0.07.

Segment Revenue

• The company has not generated any operating revenues as of March 31, 2025, and will not do so until after the completion of an initial Business Combination.

Operational Metrics

• Net Income: For the three months ended March 31, 2025, the company reported a net income of $1,020,970, primarily due to interest earned on cash held in the Trust Account amounting to $1,234,208, offset by operational costs of $213,238.
• Loss from Operations: The company reported a loss from operations of $213,238 for the three months ended March 31, 2025.

Cash Flow

• Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used in operating activities was - $146,448.
• Cash Held in Trust Account: As of March 31, 2025, cash held in the Trust Account was $120,328,139.

Unique Metrics

• Interest Income: The company generated non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering and the sale of the Private Placement Units held in the Trust Account.

Future Outlook and Strategy

• Core Business Focus: The company intends to pursue a Business Combination with a target in the deep technology sector, including artificial intelligence, quantum computing, and biotechnology, focusing on businesses in Asia.
• Non-Core Business: The company will not consummate its initial Business Combination with an entity or business with China operations through a variable interest entity (VIE) structure.
• Priority: The company has 18 months from the closing of the Initial Public Offering to consummate a Business Combination, failing which it will proceed to commence voluntary liquidation.